BPE — Moderate
Moderate BPE is one of four levels in the BI-RADS v2025 background parenchymal enhancement (BPE) classification system. It indicates that a substantial — but not extreme — proportion of the fibroglandular tissue (FGT) enhances on early post-contrast imaging.
Definition
A substantial proportion of the fibroglandular tissue demonstrates enhancement on the first post-contrast subtraction series. Enhancement is clearly more than BPE — Mild but does not approach near-complete enhancement of FGT seen in BPE — Marked. The visual estimate is qualitative — no numeric percentage threshold is codified in BI-RADS v2025.
Board Pearl
BPE is assessed on the first post-contrast subtraction images (typically ~90 seconds post-injection). Evaluating BPE on later phases overestimates enhancement level because progressive parenchymal uptake continues over time.
Four-Level BPE Scale (v2025)
| Level | Description | Impact on Interpretation |
|---|---|---|
| Minimal | Little to no FGT enhancement (includes no enhancement) | Ideal — high lesion conspicuity |
| Mild | Small amount of FGT enhancement | Generally adequate sensitivity |
| Moderate | Substantial FGT enhancement | Reduced lesion conspicuity; may obscure small enhancing lesions |
| Marked | Near-complete FGT enhancement | Significantly impaired sensitivity; consider repeat in optimal cycle phase |
Imaging Appearance
- Early post-contrast T1W fat-sat / subtraction: Visible, diffuse enhancement occupying a substantial portion of fibroglandular tissue; clearly more conspicuous than mild BPE
- MIP (Maximum Intensity Projection): Background “glow” is readily apparent, can approach the signal intensity of enhancing lesions
- T2-weighted: No direct correlate — BPE is a contrast-enhancement phenomenon only
- DWI/ADC: Normal parenchyma may show mildly restricted diffusion in areas of moderate BPE, potentially confounding ADC interpretation for small lesions
Board Pearl
BPE level does not correlate reliably with the amount of FGT. A breast with heterogeneous FGT (ACR C) can have minimal BPE, and a breast with scattered FGT (ACR B) can have moderate BPE. Always report both independently.
Clinical Relevance
Diagnostic Impact
- Moderate BPE reduces conspicuity of enhancing lesions, particularly small masses and foci
- Sensitivity of MRI decreases as BPE increases — moderate BPE represents a clinically meaningful reduction in lesion detectability compared to minimal/mild
- May mask non-mass enhancement (NME), especially NME Distribution — Focal and NME Distribution — Regional patterns that blend with background
Screening Implications
- In high-risk screening, moderate BPE does not disqualify the exam but should prompt the radiologist to scrutinize subtraction images carefully
- If a clinical concern exists and the exam is limited by moderate BPE, consider short-interval follow-up or repeat MRI at a more favorable cycle time
Hormonal and Menstrual Cycle Factors
- Premenopausal patients: BPE fluctuates with the menstrual cycle; imaging during days 7–14 (follicular phase) minimizes BPE
- Hormone replacement therapy (HRT): Can elevate BPE to moderate or marked levels; consider temporary cessation (4–6 weeks) before elective MRI if clinically appropriate
- Tamoxifen: Tends to reduce BPE over time
- Aromatase inhibitors: Generally reduce BPE
- Postmenopausal patients: BPE is typically minimal/mild; moderate BPE in a postmenopausal patient not on HRT is relatively uncommon and should be noted
Board Pearl
If a premenopausal patient has moderate BPE and the exam was performed outside the optimal window (days 7–14), state this in the report: “BPE is moderate, possibly related to suboptimal cycle timing. Correlation with menstrual history is recommended.” This documents the limitation and justifies potential repeat imaging.
Symmetry Assessment
BPE symmetry is reported separately from BPE level in v2025:
| Pattern | Significance |
|---|---|
| Symmetric moderate BPE | Expected physiologic enhancement — no additional concern |
| Asymmetric moderate BPE | Raises suspicion — asymmetric enhancement may represent underlying pathology (NME, DCIS) and warrants careful evaluation |
Board Pearl
Asymmetric BPE is more concerning than the BPE level itself. Moderate symmetric BPE is a normal variant; moderate asymmetric BPE demands targeted evaluation of the asymmetric region and may warrant BI-RADS Category 3 or BI-RADS Category 4 assessment depending on morphology.
Differential Diagnosis
When moderate BPE appears asymmetric or unusually focal, consider:
| Entity | Distinguishing Features |
|---|---|
| Physiologic moderate BPE | Bilateral, symmetric, follows FGT distribution, stable on prior exams |
| Diffuse NME | May mimic marked/moderate BPE; look for clumped or clustered ring internal enhancement |
| Regional NME (e.g., DCIS) | Segmental or regional distribution, may show clumped enhancement, correlate with mammographic calcifications |
| Inflammatory carcinoma | Skin thickening, trabecular thickening, axillary lymphadenopathy, unilateral |
| Mastitis | Clinical history of pain/erythema, skin thickening, abscess formation |
Pitfalls
- Overestimating BPE level by reading delayed-phase images instead of early post-contrast — always use the first subtraction series
- Ignoring cycle timing — reporting moderate BPE without noting luteal-phase timing misses an opportunity for a better exam
- Dismissing asymmetry — assuming moderate BPE is always benign; asymmetric moderate BPE requires targeted workup
- Confusing BPE with NME — diffuse NME can masquerade as marked/moderate BPE; evaluate internal enhancement pattern carefully (clumped or clustered ring favors NME over BPE)
- Not comparing to priors — a new increase from mild to moderate BPE should prompt consideration of hormonal changes or underlying pathology
Reporting
Per BI-RADS v2025, the Breast Tissue section of every MRI report should include:
- Amount of FGT (A–D)
- BPE level (minimal, mild, moderate, marked)
- BPE symmetry (symmetric or asymmetric)
Example: “Heterogeneous fibroglandular tissue. Moderate symmetric background parenchymal enhancement.”